Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased its securities during the specified Class Period, alleging misleading statements regarding the company's business and operations [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Telix - Defendants are accused of making false or misleading statements and failing to disclose that Telix overstated its progress with prostate cancer therapeutic candidates [3]. - The company allegedly exaggerated the quality of its supply chain and partners, leading to misleading statements about its business and prospects [3]. - The complaint claims that when the true state of Telix's business was revealed, investors experienced significant financial losses [3].
TELIX PHARMACEUTICALS (NASDAQ: TLX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by January 9, 2026